全文获取类型
收费全文 | 1473篇 |
免费 | 385篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 57篇 |
妇产科学 | 109篇 |
基础医学 | 81篇 |
口腔科学 | 23篇 |
临床医学 | 734篇 |
内科学 | 216篇 |
皮肤病学 | 14篇 |
神经病学 | 90篇 |
特种医学 | 91篇 |
外科学 | 188篇 |
综合类 | 27篇 |
预防医学 | 88篇 |
眼科学 | 8篇 |
药学 | 75篇 |
中国医学 | 1篇 |
肿瘤学 | 65篇 |
出版年
2021年 | 16篇 |
2020年 | 12篇 |
2019年 | 15篇 |
2018年 | 75篇 |
2017年 | 99篇 |
2016年 | 115篇 |
2015年 | 113篇 |
2014年 | 95篇 |
2013年 | 128篇 |
2012年 | 66篇 |
2011年 | 75篇 |
2010年 | 79篇 |
2009年 | 102篇 |
2008年 | 91篇 |
2007年 | 83篇 |
2006年 | 75篇 |
2005年 | 68篇 |
2004年 | 65篇 |
2003年 | 38篇 |
2002年 | 37篇 |
2001年 | 14篇 |
2000年 | 21篇 |
1999年 | 20篇 |
1998年 | 20篇 |
1997年 | 26篇 |
1996年 | 21篇 |
1995年 | 13篇 |
1994年 | 12篇 |
1993年 | 8篇 |
1992年 | 16篇 |
1991年 | 8篇 |
1990年 | 13篇 |
1989年 | 14篇 |
1988年 | 13篇 |
1987年 | 17篇 |
1986年 | 7篇 |
1985年 | 17篇 |
1984年 | 7篇 |
1983年 | 6篇 |
1982年 | 9篇 |
1981年 | 6篇 |
1979年 | 9篇 |
1978年 | 15篇 |
1977年 | 11篇 |
1976年 | 9篇 |
1974年 | 6篇 |
1973年 | 8篇 |
1971年 | 16篇 |
1970年 | 14篇 |
1969年 | 6篇 |
排序方式: 共有1878条查询结果,搜索用时 15 毫秒
101.
Andreas Stang Andrea Schmidt-Pokrzywniak Martin Lehnert Donald M Parkin Jaques Ferlay Norbert Bornfeld Anja Marr Karl-Heinz J?ckel 《European journal of cancer prevention》2006,15(2):165-170
Valid incidence rates of uveal melanoma (UM) from German population-based cancer registries are currently not available due to under-reporting. We conducted two case-control studies on UM at a reference centre for eye tumours and show the influence on population-based incidences of UM when data from case-control studies are linked with a cancer registry. The first case-control study (1996-1998) recruited 13 UM cases aged 35-74 years and the second case-control study (2002-2003) recruited 20 UM cases aged 20-74 residing within the population covered by the Münster Cancer Registry. After record linkage, age-truncated and standardized (World Standard Population) incidences with and without the record linkage were compared. Incidence rates based on routine cancer registration increased by a factor of 1.7 (1996-1998, age group 35-74 years) and 3.7 (2002-2003, age group 20-74 years) after record linkage with the case-control data. The supplemented age-standardized incidence of UM is 8.6 per million (20-74 years, 2002-2003) compared with the unsupplemented incidence of 2.3 per million. UM unknown to the registry were less often morphologically verified than those known to the registry. Cancer registries relying on pathology reports underestimate UM incidences if eye-preserving treatments are introduced. Close co-operation between cancer referral centres and cancer registries can substantially improve the completeness of registration. 相似文献
102.
Alexander Stojadinovic Ronald A Ghossein Axel Hoos Aviram Nissan David Marshall Maria Dudas Carlos Cordon-Cardo David P Jaques Murray F Brennan 《Journal of clinical oncology》2002,20(4):941-950
PURPOSE: To define multimolecular phenotypes of adrenocortical carcinoma (ACC) and to correlate outcome with morphologic and molecular parameters. PATIENTS AND METHODS: Clinical data were analyzed for 124 patients, histopathologic slides for 67 primary tumors, and tissue specimens for 74 patients (38 primary and 36 metastatic tumors) with ACC and for 38 normal adrenal tissue samples. Molecular expression profiles were investigated by immunohistochemistry. The prognostic significance of 12 gross and histologic parameters in 67 primary ACCs was evaluated. Morphologic and protein expression patterns were correlated with disease-specific survival (DSS). Univariate influence of prognostic factors on DSS was analyzed by log-rank test and multivariate analysis by Cox regression. RESULTS: The median follow-up period was 4.7 years. Significant predictors of DSS included distant metastasis at time of initial presentation; venous, capsular, and adjacent organ invasion; tumor necrosis, mitotic rate, atypical mitosis, and mdm-2 overexpression. Five-year DSS by number (one to six) of adverse histologic parameters was as follows: one to two, 84%; three to four, 37%; more than four, 9% (P =.005).The phenotype Ki-67(-)p53(-)mdm-2(+)cyclinD1(-)Bcl-2(-)p21(-)p27(+) was observed in 83% of normal and 3% of malignant adrenal tissue (P =.01). Molecular phenotypic expression was more heterogeneous in malignant than in normal (10 v five phenotypes) adrenal tissue. CONCLUSION: Meticulous morphologic evaluation, mitotic count, and tumor stage are essential in determining prognosis for patients with ACC. Multimolecular phenotyping demonstrates that the molecular complexity and heterogeneity of these neoplasms are such that targeted therapy needs to be patient specific. 相似文献
103.
Specific c-K-ras Gene Mutations as a Tumor-Response Marker in Locally Advanced Rectal Cancer Treated With Preoperative Chemoradiotherapy 总被引:3,自引:0,他引:3
Luna-Pérez P Segura J Alvarado I Labastida S Santiago-Payán H Quintero A 《Annals of surgical oncology》2000,7(10):727-731
Background: Forty percent of patients with colorectal cancer develop mutations in the K-ras gene.Objective: Our objective was to evaluate whether the presence of c-K-ras gene mutations is a useful tumor-response marker in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.Material and Methods: Thirty seven patients with locally advanced rectal cancer were treated with preoperative chemoradiotherapy. Four to six weeks later, surgery was performed. Specimens were classified according to the UICC-AJC classification. A segment of the tumor was obtained to analyze specific c-K-ras gene mutations. Restriction fragment length polymorphism (RFLP) and single strand confirmation polymorphism (SSCP) techniques were used with a set of probes to detect specific c-K-ras mutations in codons 12, 13, and 61. The 37 patients were divided into Group A (with mutations) and Group B (without mutations).Results: All 37 patients completed the scheduled treatment. Group A consisted of 12 patients, whose tumors were classified and specific c-K-ras mutations were located as follows: eight in codon 12, two in codon 13, and one in codon 61. Group B consisted of 25 patients. The tumors were classified and there were more early-stage tumors in Group A, whereas in Group B there were more advanced-stage tumors (P 5 .05, respectively). The mean follow-up was 36.2 6 18.3 months. All Group A patients survived, whereas 8 of the 25 patients in Group B died due to progressive metastatic disease. Survival in Group A was 100%, whereas in Group B it was 59% (P 5 .03).Conclusions: The presence of specific c-K-ras mutations is an indicator of tumor response in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy and surgery. Therefore, responding patients may be more amenable to less radical surgical procedures based on c-K-ras mutations. 相似文献
104.
105.
106.
Leaf AN Wolf BC Kirkwood JM Haselow RE 《Medical oncology (Northwood, London, England)》2000,17(1):47-51
This study of etoposide in thyroid cancer was designed to determine the activity and toxicity of etoposide in a variety of
inoperable, thyroid hormone insensitive, and radio-iodine resistant primary cancers of the thyroid. The patients were required
to have an ECOG performance status of at least 3 and no previous exposure to chemotherapy. The etoposide was given at a dose
of 140 mg/m2 daily for 3 days and every 3 weeks until progression. The study was closed after 18 months because of poor accrual. There
were no responses seen among the 10 patients accrued. The toxicity was primarily hematologic. There was no evidence of activity
of etoposide in thyroid carcinoma, although this study lacked significant power because of the poor accrual. 相似文献
107.
108.
109.
110.
Mi H Gupta A Gok MA Asher J Shenton BK Stamp S Carter V Del Rio Martin J Soomro NA Jaques BC Manas DM Talbot D 《Transplantation proceedings》2005,37(8):3272-3273
Streptokinase is used for preflush for non-heart-beating donors (NHBDs) in our center. The aim of this study was to evaluate whether the use of thrombolytic streptokinase results in the production of anti-streptokinase antibodies in the recipients after renal transplantation. Recipient sera taken prior to and at 1 and 6 months posttransplant were tested for the presence of antibodies to streptokinase using an enzyme-linked immunosorbent assay assay. No differences were detected between a group of 18 recipients who had kidneys from thrombolytic-treated NHBDs and a further group of 18 who received NHBD kidneys without such treatment. 相似文献